Neurology Clinical Trials Market Size, Share, and Trends 2024 to 2033

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology (Premium Insights)

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Neurology Clinical Trials Market 

5.1. COVID-19 Landscape: Neurology Clinical Trials Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Neurology Clinical Trials Market, By Phase

8.1. Neurology Clinical Trials Market, by Phase, 2024-2033

8.1.1. Phase I

8.1.1.1. Market Revenue and Forecast (2021-2033)

8.1.2. Phase II

8.1.2.1. Market Revenue and Forecast (2021-2033)

8.1.3. Phase III

8.1.3.1. Market Revenue and Forecast (2021-2033)

8.1.4. Phase IV Dessert

8.1.4.1. Market Revenue and Forecast (2021-2033)

Chapter 9. Global Neurology Clinical Trials Market, By Study Design

9.1. Neurology Clinical Trials Market, by Study Design, 2024-2033

9.1.1. Interventional

9.1.1.1. Market Revenue and Forecast (2021-2033)

9.1.2. Observational

9.1.2.1. Market Revenue and Forecast (2021-2033)

9.1.3. Expanded Access

9.1.3.1. Market Revenue and Forecast (2021-2033)

Chapter 10. Global Neurology Clinical Trials Market, By Indication 

10.1. Neurology Clinical Trials Market, by Indication, 2024-2033

10.1.1. Epilepsy

10.1.1.1. Market Revenue and Forecast (2021-2033)

10.1.2. Parkinson’s Disease (PD)

10.1.2.1. Market Revenue and Forecast (2021-2033)

10.1.3. Huntington’s Disease

10.1.3.1. Market Revenue and Forecast (2021-2033)

10.1.4. Stroke

10.1.4.1. Market Revenue and Forecast (2021-2033)

10.1.5. Traumatic Brain Injury (TBI)

10.1.5.1. Market Revenue and Forecast (2021-2033)

10.1.6. Amyotrophic Lateral Sclerosis (ALS)

10.1.6.1. Market Revenue and Forecast (2021-2033)

10.1.7. Muscle Regeneration

10.1.7.1. Market Revenue and Forecast (2021-2033)

10.1.8. Others

10.1.8.1. Market Revenue and Forecast (2021-2033)

Chapter 11. Global Neurology Clinical Trials Market, By Study Design

11.1. Neurology Clinical Trials Market, by Study Design, 2024-2033

11.1.1. Epilepsy

11.1.1.1. Market Revenue and Forecast (2021-2033)

11.1.2. Parkinson’s Disease (PD)

11.1.2.1. Market Revenue and Forecast (2021-2033)

11.1.3. Huntington’s Disease

11.1.3.1. Market Revenue and Forecast (2021-2033)

11.1.4. Stroke

11.1.4.1. Market Revenue and Forecast (2021-2033)

11.1.5. Traumatic Brain Injury (TBI)

11.1.5.1. Market Revenue and Forecast (2021-2033)

11.1.6. Amyotrophic Lateral Sclerosis (ALS)

11.1.6.1. Market Revenue and Forecast (2021-2033)

11.1.7. Muscle Regeneration

11.1.7.1. Market Revenue and Forecast (2021-2033)

11.1.8. Others

11.1.8.1. Market Revenue and Forecast (2021-2033)

Chapter 12. Global Neurology Clinical Trials Market, By Phase

12.1. Neurology Clinical Trials Market, by Phase, 2024-2033

12.1.1. Epilepsy

12.1.1.1. Market Revenue and Forecast (2021-2033)

12.1.2. Parkinson’s Disease (PD)

12.1.2.1. Market Revenue and Forecast (2021-2033)

12.1.3. Huntington’s Disease

12.1.3.1. Market Revenue and Forecast (2021-2033)

12.1.4. Stroke

12.1.4.1. Market Revenue and Forecast (2021-2033)

12.1.5. Traumatic Brain Injury (TBI)

12.1.5.1. Market Revenue and Forecast (2021-2033)

12.1.6. Amyotrophic Lateral Sclerosis (ALS)

12.1.6.1. Market Revenue and Forecast (2021-2033)

12.1.7. Muscle Regeneration

12.1.7.1. Market Revenue and Forecast (2021-2033)

12.1.8. Others

12.1.8.1. Market Revenue and Forecast (2021-2033)

Chapter 13. Global Neurology Clinical Trials Market, Regional Estimates and Trend Forecast

13.1. North America

13.1.1. Market Revenue and Forecast, by Phase (2021-2033)

13.1.2. Market Revenue and Forecast, by Study Design (2021-2033)

13.1.3. Market Revenue and Forecast, by Indication (2021-2033)

13.1.4. Market Revenue and Forecast, by Study Design (2021-2033)

13.1.5. Market Revenue and Forecast, by Phase (2021-2033)

13.1.6. U.S.

13.1.6.1. Market Revenue and Forecast, by Phase (2021-2033)

13.1.6.2. Market Revenue and Forecast, by Study Design (2021-2033)

13.1.6.3. Market Revenue and Forecast, by Indication (2021-2033)

13.1.6.4. Market Revenue and Forecast, by Study Design (2021-2033)

13.1.6.5. Market Revenue and Forecast, by Phase (2021-2033) 

13.1.7. Rest of North America

13.1.7.1. Market Revenue and Forecast, by Phase (2021-2033)

13.1.7.2. Market Revenue and Forecast, by Study Design (2021-2033)

13.1.7.3. Market Revenue and Forecast, by Indication (2021-2033)

13.1.7.4. Market Revenue and Forecast, by Study Design (2021-2033)

13.1.7.5. Market Revenue and Forecast, by Phase (2021-2033)

13.2. Europe

13.2.1. Market Revenue and Forecast, by Phase (2021-2033)

13.2.2. Market Revenue and Forecast, by Study Design (2021-2033)

13.2.3. Market Revenue and Forecast, by Indication (2021-2033)

13.2.4. Market Revenue and Forecast, by Study Design (2021-2033) 

13.2.5. Market Revenue and Forecast, by Phase (2021-2033) 

13.2.6. UK

13.2.6.1. Market Revenue and Forecast, by Phase (2021-2033)

13.2.6.2. Market Revenue and Forecast, by Study Design (2021-2033)

13.2.6.3. Market Revenue and Forecast, by Indication (2021-2033)

13.2.7. Market Revenue and Forecast, by Study Design (2021-2033) 

13.2.8. Market Revenue and Forecast, by Phase (2021-2033) 

13.2.9. Germany

13.2.9.1. Market Revenue and Forecast, by Phase (2021-2033)

13.2.9.2. Market Revenue and Forecast, by Study Design (2021-2033)

13.2.9.3. Market Revenue and Forecast, by Indication (2021-2033)

13.2.10. Market Revenue and Forecast, by Study Design (2021-2033)

13.2.11. Market Revenue and Forecast, by Phase (2021-2033)

13.2.12. France

13.2.12.1. Market Revenue and Forecast, by Phase (2021-2033)

13.2.12.2. Market Revenue and Forecast, by Study Design (2021-2033)

13.2.12.3. Market Revenue and Forecast, by Indication (2021-2033)

13.2.12.4. Market Revenue and Forecast, by Study Design (2021-2033)

13.2.13. Market Revenue and Forecast, by Phase (2021-2033)

13.2.14. Rest of Europe

13.2.14.1. Market Revenue and Forecast, by Phase (2021-2033)

13.2.14.2. Market Revenue and Forecast, by Study Design (2021-2033)

13.2.14.3. Market Revenue and Forecast, by Indication (2021-2033)

13.2.14.4. Market Revenue and Forecast, by Study Design (2021-2033)

13.2.15. Market Revenue and Forecast, by Phase (2021-2033)

13.3. APAC

13.3.1. Market Revenue and Forecast, by Phase (2021-2033)

13.3.2. Market Revenue and Forecast, by Study Design (2021-2033)

13.3.3. Market Revenue and Forecast, by Indication (2021-2033)

13.3.4. Market Revenue and Forecast, by Study Design (2021-2033)

13.3.5. Market Revenue and Forecast, by Phase (2021-2033)

13.3.6. India

13.3.6.1. Market Revenue and Forecast, by Phase (2021-2033)

13.3.6.2. Market Revenue and Forecast, by Study Design (2021-2033)

13.3.6.3. Market Revenue and Forecast, by Indication (2021-2033)

13.3.6.4. Market Revenue and Forecast, by Study Design (2021-2033)

13.3.7. Market Revenue and Forecast, by Phase (2021-2033)

13.3.8. China

13.3.8.1. Market Revenue and Forecast, by Phase (2021-2033)

13.3.8.2. Market Revenue and Forecast, by Study Design (2021-2033)

13.3.8.3. Market Revenue and Forecast, by Indication (2021-2033)

13.3.8.4. Market Revenue and Forecast, by Study Design (2021-2033)

13.3.9. Market Revenue and Forecast, by Phase (2021-2033)

13.3.10. Japan

13.3.10.1. Market Revenue and Forecast, by Phase (2021-2033)

13.3.10.2. Market Revenue and Forecast, by Study Design (2021-2033)

13.3.10.3. Market Revenue and Forecast, by Indication (2021-2033)

13.3.10.4. Market Revenue and Forecast, by Study Design (2021-2033)

13.3.10.5. Market Revenue and Forecast, by Phase (2021-2033)

13.3.11. Rest of APAC

13.3.11.1. Market Revenue and Forecast, by Phase (2021-2033)

13.3.11.2. Market Revenue and Forecast, by Study Design (2021-2033)

13.3.11.3. Market Revenue and Forecast, by Indication (2021-2033)

13.3.11.4. Market Revenue and Forecast, by Study Design (2021-2033)

13.3.11.5. Market Revenue and Forecast, by Phase (2021-2033)

13.4. MEA

13.4.1. Market Revenue and Forecast, by Phase (2021-2033)

13.4.2. Market Revenue and Forecast, by Study Design (2021-2033)

13.4.3. Market Revenue and Forecast, by Indication (2021-2033)

13.4.4. Market Revenue and Forecast, by Study Design (2021-2033)

13.4.5. Market Revenue and Forecast, by Phase (2021-2033)

13.4.6. GCC

13.4.6.1. Market Revenue and Forecast, by Phase (2021-2033)

13.4.6.2. Market Revenue and Forecast, by Study Design (2021-2033)

13.4.6.3. Market Revenue and Forecast, by Indication (2021-2033)

13.4.6.4. Market Revenue and Forecast, by Study Design (2021-2033)

13.4.7. Market Revenue and Forecast, by Phase (2021-2033)

13.4.8. North Africa

13.4.8.1. Market Revenue and Forecast, by Phase (2021-2033)

13.4.8.2. Market Revenue and Forecast, by Study Design (2021-2033)

13.4.8.3. Market Revenue and Forecast, by Indication (2021-2033)

13.4.8.4. Market Revenue and Forecast, by Study Design (2021-2033)

13.4.9. Market Revenue and Forecast, by Phase (2021-2033)

13.4.10. South Africa

13.4.10.1. Market Revenue and Forecast, by Phase (2021-2033)

13.4.10.2. Market Revenue and Forecast, by Study Design (2021-2033)

13.4.10.3. Market Revenue and Forecast, by Indication (2021-2033)

13.4.10.4. Market Revenue and Forecast, by Study Design (2021-2033)

13.4.10.5. Market Revenue and Forecast, by Phase (2021-2033)

13.4.11. Rest of MEA

13.4.11.1. Market Revenue and Forecast, by Phase (2021-2033)

13.4.11.2. Market Revenue and Forecast, by Study Design (2021-2033)

13.4.11.3. Market Revenue and Forecast, by Indication (2021-2033)

13.4.11.4. Market Revenue and Forecast, by Study Design (2021-2033)

13.4.11.5. Market Revenue and Forecast, by Phase (2021-2033)

13.5. Latin America

13.5.1. Market Revenue and Forecast, by Phase (2021-2033)

13.5.2. Market Revenue and Forecast, by Study Design (2021-2033)

13.5.3. Market Revenue and Forecast, by Indication (2021-2033)

13.5.4. Market Revenue and Forecast, by Study Design (2021-2033)

13.5.5. Market Revenue and Forecast, by Phase (2021-2033)

13.5.6. Brazil

13.5.6.1. Market Revenue and Forecast, by Phase (2021-2033)

13.5.6.2. Market Revenue and Forecast, by Study Design (2021-2033)

13.5.6.3. Market Revenue and Forecast, by Indication (2021-2033)

13.5.6.4. Market Revenue and Forecast, by Study Design (2021-2033)

13.5.7. Market Revenue and Forecast, by Phase (2021-2033)

13.5.8. Rest of LATAM

13.5.8.1. Market Revenue and Forecast, by Phase (2021-2033)

13.5.8.2. Market Revenue and Forecast, by Study Design (2021-2033)

13.5.8.3. Market Revenue and Forecast, by Indication (2021-2033)

13.5.8.4. Market Revenue and Forecast, by Study Design (2021-2033)

13.5.8.5. Market Revenue and Forecast, by Phase (2021-2033)

Chapter 14. Company Profiles

14.1. IQVIA

14.1.1. Company Overview

14.1.2. Product Offerings

14.1.3. Financial Performance

14.1.4. Recent Initiatives

14.2. Biogen

14.2.1. Company Overview

14.2.2. Product Offerings

14.2.3. Financial Performance

14.2.4. Recent Initiatives

14.3. Aurora Healthcare

14.3.1. Company Overview

14.3.2. Product Offerings

14.3.3. Financial Performance

14.3.4. Recent Initiatives

14.4. GlaxoSmithKline Plc.

14.4.1. Company Overview

14.4.2. Product Offerings

14.4.3. Financial Performance

14.4.4. Recent Initiatives

14.5. Icon Plc.

14.5.1. Company Overview

14.5.2. Product Offerings

14.5.3. Financial Performance

14.5.4. Recent Initiatives

14.6. Syneous Health

14.6.1. Company Overview

14.6.2. Product Offerings

14.6.3. Financial Performance

14.6.4. Recent Initiatives

14.7. Charles River Laboratories

14.7.1. Company Overview

14.7.2. Product Offerings

14.7.3. Financial Performance

14.7.4. Recent Initiatives

14.8. Med pace

14.8.1. Company Overview

14.8.2. Product Offerings

14.8.3. Financial Performance

14.8.4. Recent Initiatives

14.9. Covance

14.9.1. Company Overview

14.9.2. Product Offerings

14.9.3. Financial Performance

14.9.4. Recent Initiatives

14.10. Novartis AG

14.10.1. Company Overview

14.10.2. Product Offerings

14.10.3. Financial Performance

14.10.4. Recent Initiatives

Chapter 15. Research Methodology

15.1. Primary Research

15.2. Secondary Research

15.3. Assumptions

Chapter 16. Appendix

16.1. About Us

16.2. Glossary of Terms